The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.
Leslie Citrome, MD, MPH,1 Christoph U. Correll, MD,2-5 Roger S. McIntyre, MD,6 Mark S. Todtenkopf, PhD,7 Christina Arevalo, MS,7 James A. McGrory, PhD,8 David McDonnell, MD8
1New York Medical College, Valhalla, NY, USA; 2Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; 3Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 4Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany; 5German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany; 6University of Toronto, Department of Psychiatry and Pharmacology and Toxicology, Toronto, ON, Canada; 7Alkermes, Inc., Waltham, MA, USA; 8Alkermes Pharma Ireland Ltd., Dublin, Ireland
